Clinical Trial Update: Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for derazantinib alone or with paclitaxel, ramucirumab, or atezolizumab in gastric adenocarcinoma; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Derazantinib (derazantinib)
• PACLITAXEL (PACLITAXEL)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Basilea Pharmaceutica | Conditions: Gastric Adenocarcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-04-04